Reid Huber

Reid M.
Huber is Director at Tango Therapeutics Sub, Inc. since 2019, Director at Asher Biotherapeutics, Inc. since 2021, Director at Synnovation Therapeutics, Inc., Director at Terremoto Biosciences, Inc. since 2021, Independent Director at Rapport Therapeutics, Inc. since 2022, and Partner at Third Rock Ventures LLC since 2018.
Former roles include Chief Executive Officer at Merida Biosciences, Inc., Chief Executive Officer & Director at MOMA Therapeutics, Inc. from 2020 to 2021, Independent Director at Bellicum Pharmaceuticals, Inc. from 2014 to 2024, Director at American Cancer Society, Inc., Director at Insitro, Inc., Independent Director at Cargo Therapeutics, Inc. from 2023 to 2025, Independent Director at Tango Therapeutics, Inc. from 2019 to 2023, Chief Scientific Officer & Executive VP at Incyte Corp.
from 2014 to 2018, and Principal Research Scientist at DuPont Pharmaceuticals Co. from 1998 to 2002.
Education includes an undergraduate degree from Murray State University (Kentucky) conferred in 1994 and a doctorate from Washington University School of Medicine conferred in 1998.